se ha leído el artículo
array:19 [ "pii" => "X0211699500025427" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:75" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1634 "formatos" => array:3 [ "EPUB" => 163 "HTML" => 1192 "PDF" => 279 ] ] "itemSiguiente" => array:15 [ "pii" => "X0211699500025419" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:76" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1444 "formatos" => array:3 [ "EPUB" => 154 "HTML" => 1019 "PDF" => 271 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "«HIPERTENSIÓN Y ENFERMEDAD CARDIOVASCULAR EN PACIENTES CON INSUFICIENCIA RENAL CRÓNICA» Effects of hyperparathyroidism in the pathogenesis of hypertension, left ventricular hypertrophy and cardiovascular disease in CRF patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "76" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. B. DRÜEKE" "autores" => array:1 [ 0 => array:1 [ "nombre" => "T. B. DRÜEKE" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025419?idApp=UINPBA000064" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025419/v0_201502091333/en/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699500025435" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:73-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2546 "formatos" => array:3 [ "EPUB" => 166 "HTML" => 2049 "PDF" => 331 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Tratamiento de la hipertensión después del trasplante renal con antagonistas de los Receptores de la Angiotensina" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "73" "paginaFinal" => "74" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. DEL CASTILLO" "autores" => array:1 [ 0 => array:1 [ "nombre" => "D. DEL CASTILLO" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025435?idApp=UINPBA000064" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025435/v0_201502091333/es/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "«NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "75" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "G. REMUZZI" "autores" => array:1 [ 0 => array:1 [ "nombre" => "G. REMUZZI" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 «NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy G. Remuzzi, MD About 30% of insulin dependent diabetic (IDD) and 15-60% of non-insulin-dependent diabetic (NIDD) patients develop diabetic nephropathy (DN), a syndrome of macroalbuminuria, systemic hypertension and declining glomerular filtration rate (GFR), associated with a 20 to 40-fold increased risk of cardiovascular mortality. DN, the leading cause of end stage renal failure in Western countries, is invariably heralded by the appearance of persistent microalbuminuria (incipient nephropathy: IN). Every year, 4.4% to 6.8% of IDD patients on conventional insulin therapy and 4.6% of NIDD patients progress to micro-albuminuria. A higher rate of progression is reported in smokers and in patients with higher blood pressure. Thus, microalbuminuria is now considered an early marker of renal involvement in diabetes, and its prevention can be taken as to indicate primary prevention of DN. It is well established that angiotensin converting enzyme (ACE) inhibitors delay the progression of IN to overt DN (secondary prevention) either in IDD and in NIDD and remarkably decrease disease progression to uremia and overall cardiovascular mortality in IDD patients with overt DN. Whether early treatment with ACE inhibitors in normoalbuminuric diabetic patients may effectively prevent progression to microalbuminuria (primary prevention) is not established so far. However, preliminary evidence is available that the incidence of microalbuminuria may be reduced by ACE inhibition therapy in hypertensive NIDD patients. Calcium channel blockers (CCBs) inhibit the vasoconstrictor as well as both the hypertrophic and hyperplastic effects of angiotensin II and other mytogens on mesangial and vascular smooth muscle cells through blockade of calcium dependent mechanisms. Early studies, however, demonstrate marked differences between the antiproteinuric effects of dihydropyridine CCBs and nondihydropyridine CCBs, such as verapamil and diltiazem. Recent data support the concept that differences in antiproteinuric response subclasses relate to their differential effects on glomerular permeability, that is, dihydropyridine CCBs do not ameliorate glomerular barrier perm-selectivity whereas nondihydropyridine CCBs attenuate it. Failure to restore the sieving properties of the glomerular barrier increases protein ultrafiltration and enhanced protein traffic in the long-term contributes to the progression of renal injury independently of the underlying renal disease. Recent studies found that nondihydropyridine CCBs may have the same reno-protective potential of ACE inhibitors either in experimental models of progressive renal disease and in NIDD patients. The association of ACE inhibitors with nondihydropyridine CCBs may even more effectively than the two agents alone decrease, at comparable level of blood pressure control, proteinuria and prevent glomerulosclerosis in experimental diabetes and in hypertensive stroke-prone rats. Additionally, recent studies document that the association of ACE inhibitors with nondihydropyridine CCBs reduces urinary albumin excretion rate more effectively than the two agents alone in hypertensive NIDDM patients either with incipient or overt nephropathy. Furthermore, in proteinuric NIDDM patients, the combination of these classes of agents appears to slow GFR decline and to yield the lowest side effect profile over either agent alone in diabetic patients with overt nephropathy. Lastly, the association of a calcium channel blocker to ACE inhibition therapy in hypertensive diabetics may reduce the need for additional diuretic therapy that has been associated with an excess mortality in diabetic mellitus. However, whether the association may more effectively than ACE inhibitors alone prevent the onset of microalbuminuria (primary prevention) or delay the progression from microalbuminuria to macroalbuminuria (secondary prevention) is not established so far. 75 " "pdfFichero" => "P7-E170-S140-A1912.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025427/v0_201502091333/en/main.assets" "Apartado" => array:4 [ "identificador" => "35407" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Suplementos" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025427/v0_201502091333/en/P7-E170-S140-A1912.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025427?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 7 | 13 | 20 |
2024 Octubre | 50 | 33 | 83 |
2024 Septiembre | 48 | 29 | 77 |
2024 Agosto | 64 | 54 | 118 |
2024 Julio | 36 | 38 | 74 |
2024 Junio | 47 | 33 | 80 |
2024 Mayo | 63 | 40 | 103 |
2024 Abril | 41 | 23 | 64 |
2024 Marzo | 40 | 22 | 62 |
2024 Febrero | 37 | 32 | 69 |
2024 Enero | 25 | 21 | 46 |
2023 Diciembre | 27 | 28 | 55 |
2023 Noviembre | 33 | 28 | 61 |
2023 Octubre | 27 | 34 | 61 |
2023 Septiembre | 29 | 27 | 56 |
2023 Agosto | 29 | 29 | 58 |
2023 Julio | 38 | 27 | 65 |
2023 Junio | 41 | 17 | 58 |
2023 Mayo | 39 | 30 | 69 |
2023 Abril | 21 | 18 | 39 |
2023 Marzo | 16 | 17 | 33 |
2023 Febrero | 19 | 18 | 37 |
2023 Enero | 23 | 25 | 48 |
2022 Diciembre | 30 | 19 | 49 |
2022 Noviembre | 21 | 21 | 42 |
2022 Octubre | 26 | 40 | 66 |
2022 Septiembre | 24 | 24 | 48 |
2022 Agosto | 26 | 39 | 65 |
2022 Julio | 28 | 37 | 65 |
2022 Junio | 27 | 23 | 50 |
2022 Mayo | 20 | 24 | 44 |
2022 Abril | 29 | 31 | 60 |
2022 Marzo | 26 | 42 | 68 |
2022 Febrero | 22 | 41 | 63 |
2022 Enero | 20 | 23 | 43 |
2021 Diciembre | 13 | 32 | 45 |
2021 Noviembre | 28 | 26 | 54 |
2021 Octubre | 36 | 37 | 73 |
2021 Septiembre | 15 | 24 | 39 |
2021 Agosto | 18 | 17 | 35 |
2021 Julio | 31 | 28 | 59 |
2021 Junio | 14 | 7 | 21 |
2021 Mayo | 24 | 16 | 40 |
2021 Abril | 29 | 22 | 51 |
2021 Marzo | 27 | 11 | 38 |
2021 Febrero | 23 | 8 | 31 |
2021 Enero | 15 | 9 | 24 |
2020 Diciembre | 17 | 12 | 29 |
2020 Noviembre | 9 | 5 | 14 |
2020 Octubre | 13 | 2 | 15 |
2020 Septiembre | 8 | 0 | 8 |
2020 Agosto | 17 | 5 | 22 |
2020 Julio | 12 | 7 | 19 |
2020 Junio | 16 | 6 | 22 |
2020 Mayo | 15 | 9 | 24 |
2020 Abril | 28 | 14 | 42 |
2020 Marzo | 12 | 11 | 23 |
2020 Febrero | 25 | 18 | 43 |
2020 Enero | 34 | 13 | 47 |
2019 Diciembre | 17 | 6 | 23 |
2019 Noviembre | 8 | 1 | 9 |
2019 Octubre | 8 | 3 | 11 |
2019 Septiembre | 7 | 15 | 22 |
2019 Agosto | 8 | 7 | 15 |
2019 Julio | 14 | 11 | 25 |
2019 Junio | 9 | 7 | 16 |
2019 Mayo | 8 | 8 | 16 |
2019 Abril | 26 | 29 | 55 |
2019 Marzo | 14 | 8 | 22 |
2019 Febrero | 6 | 13 | 19 |
2019 Enero | 14 | 8 | 22 |
2018 Diciembre | 24 | 17 | 41 |
2018 Noviembre | 34 | 9 | 43 |
2018 Octubre | 36 | 10 | 46 |
2018 Septiembre | 18 | 4 | 22 |
2018 Agosto | 21 | 11 | 32 |
2018 Julio | 18 | 7 | 25 |
2018 Junio | 11 | 6 | 17 |
2018 Mayo | 16 | 9 | 25 |
2018 Abril | 15 | 4 | 19 |
2018 Marzo | 14 | 3 | 17 |
2018 Febrero | 16 | 4 | 20 |
2018 Enero | 9 | 3 | 12 |
2017 Diciembre | 10 | 4 | 14 |
2017 Noviembre | 14 | 7 | 21 |
2017 Octubre | 12 | 3 | 15 |
2017 Septiembre | 7 | 3 | 10 |
2017 Agosto | 16 | 6 | 22 |
2017 Julio | 6 | 3 | 9 |
2017 Junio | 10 | 13 | 23 |
2017 Mayo | 4 | 1 | 5 |
2017 Abril | 4 | 1 | 5 |
2017 Marzo | 6 | 2 | 8 |
2017 Febrero | 5 | 1 | 6 |
2017 Enero | 2 | 1 | 3 |
2016 Diciembre | 7 | 2 | 9 |
2016 Noviembre | 17 | 3 | 20 |
2016 Octubre | 41 | 4 | 45 |
2016 Septiembre | 36 | 1 | 37 |
2016 Agosto | 34 | 2 | 36 |
2016 Julio | 48 | 0 | 48 |
2016 Junio | 73 | 0 | 73 |
2016 Mayo | 84 | 0 | 84 |
2016 Abril | 38 | 0 | 38 |
2016 Marzo | 35 | 0 | 35 |
2016 Febrero | 29 | 0 | 29 |
2016 Enero | 30 | 0 | 30 |
2015 Diciembre | 44 | 0 | 44 |
2015 Noviembre | 37 | 0 | 37 |
2015 Octubre | 26 | 0 | 26 |
2015 Septiembre | 34 | 0 | 34 |
2015 Agosto | 19 | 0 | 19 |
2015 Julio | 27 | 0 | 27 |
2015 Junio | 8 | 0 | 8 |
2015 Mayo | 13 | 0 | 13 |